Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Rights Issue 2024

By Michael FriisHead of Equities
ExpreS2ion Biotech Holding

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

ExpreS2ion Biotechnologies is carrying out a rights issue with preferential rights for existing shareholders, amounting to approximately SEK 60 million. The company published its prospectus the 5 June 2024.

CEO Bent U. Frandsen and CFO Keith Alexander will join us on 14 June at 11.00 and take a deeper dive into details of the rights issue and warrant programs, timetable, rationale for the capital raise, and use of proceeds.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 14.16, 7 June 2024.

Recent videos

Herantis Pharma as an Investment | Life Science Night Dec 9, 2025
09.12.2025, 22.11 Herantis Pharma
Aiforia as an Investment | Life Science Night Dec 9, 2025
09.12.2025, 22.10 Aiforia Technologies
Orion as an Investment | Life Science Night Dec. 9, 2025
09.12.2025, 22.10 Orion
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
09.12.2025, 22.09 Aiforia Technologies
Life Science Night | December 9, 2025
09.12.2025, 14.30 Orion
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.